Vivos Therapeutics Secures Medicare Approval for VidaSleep Oral Appliance

July 1, 2025

DENVER, Colo., Jul 01, 2025 (247marketnews.com)- Vivos Therapeutics (NASDAQ:VVOS) reported that the VidaSleep oral appliance has been officially approved by the Centers for Medicare & Medicaid Services (CMS) Pricing, Data Analysis and Coding (PDAC) contractor. The device, which incorporates Vivos’ patented and FDA-cleared Unilateral Bite Block technology, is now authorized for use in the treatment of mild to moderate OSA and snoring in adults.

With an estimated 80 million Americans affected by OSA, and more than 80% of cases undiagnosed, Vivos is positioned to address one of the most pressing unmet needs in U.S. healthcare. The CMS decision also has broader implications: Medicare coverage often leads to adoption by commercial payers, significantly expanding the company’s total addressable market.

The PDAC approval adds VidaSleep to the same CMS coverage list as the Vivos mmRNA appliance, unlocking reimbursable access to millions of Medicare beneficiaries seeking alternatives to traditional CPAP machines and surgical procedures. Vivos now stands alone as the only company with two Medicare-covered oral appliances, both offering distinct, patented technologies designed to address the root causes of OSA, giving providers and patients multiple clinically validated and financially accessible treatment paths.

Kirk Huntsman, CEO and Chairman of Vivos Therapeutics, stated, “The PDAC approval of VidaSleep is another milestone achievement for Vivos, strategically positioning us to significantly augment our presence in the value-based care segment of the sleep apnea market. While mmRNA remains our premium solution for complex cases, VidaSleep delivers positive clinical outcomes through an optimized design that maximizes accessibility—proving that ‘cost-effective’ doesn’t mean ‘compromise.’ This dual-device approach allows us to serve every tier of the estimated $36 billion sleep therapy market, from Medicare beneficiaries to commercial payers, while maintaining our compelling gross profit margins. Just as importantly, it empowers thousands more clinicians to adopt our technology, knowing they now have multiple reimbursed options to match patient needs.”

The VidaSleep appliance employs Vivos’ proprietary Unilateral Bite Block technology for targeted airway support, while the mmRNA appliance is part of the FDA-cleared Vivos CARE product line, designed for moderate to severe OSA in both adults and children.

With this latest regulatory milestone, Vivos continues to solidify its role as a leader in non-invasive, next-generation OSA therapies, offering clinicians and patients broader access, flexibility, and confidence in treatment outcomes.

About 24/7 Market News
As a pioneer in digital financial market media, 24/7 Market News (24/7MN) is dedicated to the swift distribution of financial market news and information. 24/7 MN incorporates comprehensive corporate communications resources and tools to engage the investment community. Visit 24/7 Market News website here.

24/7 MARKET NEWS, INC Disclaimer
Please go to https://247marketnews.com/disclaimer/ for disclaimer information.

CONTACT:
24/7 Market News
Editor@247marketnews.com

Related news for (VVOS)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.